Tralokinumab

Tralokinumab is a human monoclonal antibody which targets the cytokine interleukin 13,[1] and is designed for the treatment of asthma and other inflammatory diseases.[2] Tralokinumab was discovered by Cambridge Antibody Technology scientists, using Ribosome Display, as CAT-354[3] and taken through pre-clinical and early clinical development.[4] After 2007 it has been developed by MedImmune, a member of the AstraZeneca group, where it is currently in Ph3 testing for asthma and Ph2b testing for atopic dermatitis.[5][6] This makes it one of the few fully internally discovered and developed drug candidates in AstraZeneca's late stage development pipeline.

Tralokinumab
Tralokinumab Fab fragment bound to IL-13. From PDB 5L6Y.
Monoclonal antibody
TypeWhole antibody
SourceHuman
TargetIL-13
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6374H9822N1698O2014S44
Molar mass143875.20 g·mol−1
 NY (what is this?)  (verify)

Discovery and Development

Tralokinumab (CAT-354) was discovered by Cambridge Antibody Technology scientists[7] using protein optimization based on Ribosome Display.[8] They used the extensive data sets from ribosome display to patent protect CAT-354 in a world-first of sequence-activity-relationship claims.[7] In 2004, clinical development of CAT-354 was initiated with this first study completing in 2005.[9] On 21 July 2011, MedImmune LLC initiated a Ph2b, randomized, double-blind study to evaluate the efficacy of tralokinumab in adults with asthma.[10]

In 2016, MedImmune and AstraZeneca were developing tralokinumab for asthma (Ph3) and atopic dermatitis (Ph2b) while clinical development for moderate-to-severe ulcerative colitis and idiopathic pulmonary fibrosis (IPF) have been discontinued.[9] In July of that year AstraZeneca licensed Tralokinumab to LEO Pharma for skin diseases[11].

A phase 2b study of Tralokinumab found that treatment was associated with early and sustained improvements in atopic dermatitis symptoms and tralokinumab had an acceptable safety and tolerability profile, thereby providing evidence for targeting IL-13 in patients with atopic dermatitis[12].

On 15 June 2017, Leo Pharma announced that they were starting phase 3 clinical trails with tralokinumab in atopic dermatitis[13]

References

  1. Kopf, Manfred; Bachmann, Martin F.; Marsland, Benjamin J. (2010). "Averting inflammation by targeting the cytokine environment". Nature Reviews Drug Discovery. 9 (9): 703–18. doi:10.1038/nrd2805. PMID 20811382.
  2. "Statement On A Nonproprietary Name Adopted By The USAN Council: Tralokinumab" (PDF). American Medical Association.
  3. Thom, G; Cockroft, AC; Buchanan, AG; Candotti, CJ; Cohen, ES; Lowne, D; Monk; Shorrock-Hart, CP; Jermutus, L; Minter, RR. "Probing a protein–protein interaction by in vitro evolution" [P]. Proc. Natl. Acad. Sci. USA. 103: 7619–7624. doi:10.1073/pnas.0602341103. PMC 1458619. PMID 16684878.
  4. May, RD; Monk, PD; Cohen, ES; Manuel, D; Dempsey, F; Davis, NHE; Dodd, AJ; Corkill, DJ; et al. (2012). "Preclinical development of CAT-354, an IL-13 neutralizing antibody, for the treatment of severe uncontrolled asthma". British Journal of Pharmacology. 166 (1): 177–193. doi:10.1111/j.1476-5381.2011.01659.x. PMC 3415647. PMID 21895629.
  5. "Pipeline". MedImmune. Retrieved 11 June 2013.
  6. "Studies found for CAT-354". ClinicalTrials.gov. Retrieved 11 June 2013.
  7. Human Antibody Molecules for Il-13, retrieved 2015-07-26
  8. Jermutus, Lutz; Honegger, Annemarie; Schwesinger, Falk; Hanes, Jozef; Plückthun, Andreas (2001-01-02). "Tailoring in vitro evolution for protein affinity or stability". Proceedings of the National Academy of Sciences. 98 (1): 75–80. doi:10.1073/pnas.98.1.75. ISSN 0027-8424. PMC 14547. PMID 11134506.
  9. "Tralokinumab - AdisInsight". adisinsight.springer.com. Retrieved 2016-02-20.
  10. Clinical trial number NCT01402986 for "A Phase 2b, Randomized, Double-blind Study to Evaluate the Efficacy of Tralokinumab in Adults With Asthma" at ClinicalTrials.gov
  11. https://www.astrazeneca.com/media-centre/press-releases/2016/astrazeneca-enters-licensing-agreements-with-leo-pharma-in-skin-diseases-01072016.html
  12. "Treatment of atopic dermatitis with tralokinumab, an anti-IL-13 mAb". J Allergy Clin Immunol. doi:10.1016/j.jaci.2018.05.029.
  13. "LEO Pharma starts phase 3 clinical study for tralokinumab in atopic dermatitis". leo-pharma.com.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.